X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) had its price objective lowered by stock analysts at Oppenheimer from $5.00 to $4.00 in a research report issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s target price points to a potential upside of 376.25% from the company’s current price. Oppenheimer also issued estimates for X4 Pharmaceuticals’ FY2026 earnings at $0.03 EPS and FY2027 earnings at $0.31 EPS.
A number of other brokerages have also recently issued reports on XFOR. HC Wainwright cut their target price on shares of X4 Pharmaceuticals from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Wednesday. Piper Sandler began coverage on shares of X4 Pharmaceuticals in a report on Sunday, December 11th. They issued an “overweight” rating and a $3.00 target price on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $3.00 target price on shares of X4 Pharmaceuticals in a report on Wednesday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $5.71.
X4 Pharmaceuticals Stock Performance
Shares of NASDAQ XFOR opened at $0.84 on Friday. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.30. The firm’s 50-day moving average price is $0.97 and its two-hundred day moving average price is $1.28. X4 Pharmaceuticals has a 52-week low of $0.65 and a 52-week high of $2.41. The stock has a market capitalization of $58.15 million, a P/E ratio of -0.45 and a beta of 0.56.
Insider Buying and Selling at X4 Pharmaceuticals
In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 27,721 shares of the firm’s stock in a transaction that occurred on Monday, February 13th. The shares were sold at an average price of $0.93, for a total value of $25,780.53. Following the sale, the chief financial officer now owns 146,196 shares in the company, valued at $135,962.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 54,692 shares of company stock worth $50,864. 95.90% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. LexAurum Advisors LLC acquired a new position in shares of X4 Pharmaceuticals during the third quarter valued at approximately $27,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of X4 Pharmaceuticals during the third quarter valued at approximately $39,000. Virtu Financial LLC acquired a new position in shares of X4 Pharmaceuticals during the first quarter valued at approximately $45,000. Jane Street Group LLC acquired a new position in shares of X4 Pharmaceuticals during the first quarter valued at approximately $64,000. Finally, Morgan Stanley increased its stake in shares of X4 Pharmaceuticals by 32.9% during the fourth quarter. Morgan Stanley now owns 76,057 shares of the company’s stock valued at $76,000 after acquiring an additional 18,820 shares during the period. Institutional investors and hedge funds own 56.46% of the company’s stock.
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003.
Receive News & Ratings for X4 Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for X4 Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.